Vanguard Group’s Cerevel Therapeutics Holdings CERE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-7,154,343
Closed -$293M – 4433
2024
Q2
$293M Sell
7,154,343
-309,568
-4% -$12.9M 0.01% 1276
2024
Q1
$315M Buy
7,463,911
+88,941
+1% +$3.74M 0.01% 1261
2023
Q4
$313M Buy
7,374,970
+1,003,594
+16% +$28.8M 0.01% 1259
2023
Q3
$139M Buy
6,371,376
+708,826
+13% +$17.7M ﹤0.01% 1631
2023
Q2
$180M Sell
5,662,550
-464,030
-8% -$14.2M ﹤0.01% 1517
2023
Q1
$149M Buy
6,126,580
+88,119
+1% +$2.59M ﹤0.01% 1609
2022
Q4
$190M Buy
6,038,461
+164,460
+3% +$4.64M 0.01% 1463
2022
Q3
$166M Buy
5,874,001
+861,581
+17% +$25.7M ﹤0.01% 1500
2022
Q2
$133M Buy
5,012,420
+202,727
+4% +$5.76M ﹤0.01% 1653
2022
Q1
$168M Buy
4,809,693
+7,856
+0.2% +$229K ﹤0.01% 1652
2021
Q4
$156M Buy
4,801,837
+108,678
+2% +$3.83M ﹤0.01% 1744
2021
Q3
$138M Buy
4,693,159
+1,168,443
+33% +$32.8M ﹤0.01% 1800
2021
Q2
$90.3M Buy
3,524,716
+296,575
+9% +$4.25M ﹤0.01% 2045
2021
Q1
$44.3M Buy
3,228,141
+82,067
+3% +$1.2M ﹤0.01% 2384
2020
Q4
$52.2M Buy
+3,146,074
New +$40.9M ﹤0.01% 2178

Other funds holding CERE

Vanguard Group's CERE Position: Q3 2024 in Review

Vanguard Group sold out of Cerevel Therapeutics Holdings (CERE) in Q3 2024, closing a stake of 7,154,343 shares — an estimated $293M sold.

Vanguard Group first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $315M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Vanguard Group reported no remaining Cerevel Therapeutics Holdings position as of Q3 2024 after selling out during the quarter.
  • Vanguard Group sold 7,154,343 Cerevel Therapeutics Holdings shares in Q3 2024, an estimated $293M.
  • Vanguard Group first reported a position in Cerevel Therapeutics Holdings in Q4 2020 and held it in 15 quarters.
  • Vanguard Group's Cerevel Therapeutics Holdings position peaked at $315M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings as of Q3 2024.

Based on Vanguard Group's 13F filing for Q3 2024, filed 13 Nov 2024.